Sunovion Sales Rep Draws FDA Promotional Letter For Declaring Broader Latuda Label Inevitable
This article was originally published in The Pink Sheet Daily
Executive Summary
While admitting that Sunovion Pharmaceuticals Inc.’s schizophrenia drug Latuda (lurasidone) does not yet have an indication for bipolar I disorder, a sales rep told a psychiatrist it could still be used to treat that condition, FDA’s Office of Prescription Drug Promotion says in a “notice of violation” letter.